Deciphera Pharmaceuticals, Inc. 4/A SEC Filings

Filed On	Filing
20 Feb 2020	Form 4/A: Friedman Franklin Stuart, Director Granted 23,400 Stock Option (Right to Buy)
20 Feb 2020	Form 4/A: Squarer Ron, Director Granted 21,900 Stock Option (Right to Buy)
22 Jan 2020	Form 4/A: Flynn Daniel Lee, Chief Scientific Officer Exercised 10,106 Stock Option (Right to Buy)

Comments